Latest Regulatory News

Neometals has upgraded the Ironclad gold deposit resource at its Barrambie Project to 15,000 ounces, with a significant portion now classified as Indicated, underpinning plans for near-term development.

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Galilee Energy has confirmed the Zydeco-1 well is drill-ready following enhanced 3D seismic analysis, aiming to tap up to 8 billion cubic feet of gas and 0.5 million barrels of condensate in Louisiana with spudding planned for the second quarter of 2026.

Buxton Resources has secured all necessary permits and funding to launch its inaugural drilling campaign at the Madman copper-gold project in Western Australia, targeting a promising Havieron-style magnetic anomaly.

BPM Minerals has resumed exploration at its Forelands Gold Project in WA, launching a 7,500m drilling campaign at Beachcomber and advancing Bonnie & Clyde towards maiden drilling. The project shows strong potential for a Tropicana-style gold discovery.

Pioneer Minerals reports a remarkable 17.6-fold upgrade in tungsten grade from historic tailings at its Springfield Tungsten Mine, advancing its North Pine Project in Idaho with promising metallurgical test results.

Suncorp Group Limited has updated the dividend reinvestment price for its fully franked ordinary dividend relating to the six months ending December 2025. The dividend of 17 cents per share will be paid on 31 March 2026, with flexible currency options for shareholders.

Novo Resources Corp. has issued a prospectus offering free New Options to recent placement participants and joint lead managers, aiming to support its exploration projects in Western Australia and Victoria. The options, exercisable at A$0.15 and expiring in three years, could raise significant capital upon exercise, subject to shareholder approval.

Hubify has provided detailed terms of its $250,000 equity investment in Australian AI firm HubLab, reinforcing its AI-first growth ambitions targeting enterprise and government sectors.

L1 Long Short Fund Limited has updated its dividend notification to include the Dividend Reinvestment Plan price, confirming a fully franked quarterly dividend for shareholders.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.